These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 22819090

  • 1. Early psoriatic arthritis.
    Gladman DD.
    Rheum Dis Clin North Am; 2012 May; 38(2):373-86. PubMed ID: 22819090
    [Abstract] [Full Text] [Related]

  • 2. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
    Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT, Freundlich B.
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
    [Abstract] [Full Text] [Related]

  • 3. Composite measures in psoriatic arthritis: GRAPPA 2008.
    Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A.
    J Rheumatol; 2010 Feb; 37(2):453-61. PubMed ID: 20147481
    [Abstract] [Full Text] [Related]

  • 4. Development of a preliminary composite disease activity index in psoriatic arthritis.
    Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale J D, Helliwell P, FitzGerald O.
    Ann Rheum Dis; 2011 Feb; 70(2):272-7. PubMed ID: 21115550
    [Abstract] [Full Text] [Related]

  • 5. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR.
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [Abstract] [Full Text] [Related]

  • 6. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
    Mease PJ, Heckaman M, Kary S, Kupper H.
    J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
    [Abstract] [Full Text] [Related]

  • 7. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 8. Psoriatic rheumatism. Inflammatory arthropathy.
    Macovei L, Brujbu I.
    Rev Med Chir Soc Med Nat Iasi; 2014 Apr; 118(1):45-51. PubMed ID: 24741774
    [Abstract] [Full Text] [Related]

  • 9. The treatment of enthesitis in psoriatic arthritis.
    Kumar N, Kay LJ, Walker DJ.
    J Rheumatol; 2004 Nov; 31(11):2311-2; author reply 2312-3. PubMed ID: 15536671
    [No Abstract] [Full Text] [Related]

  • 10. Rituximab in psoriatic arthritis: an exploratory evaluation.
    Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayová H, Leeb B, Machold KP, Graninger WB, Smolen JS.
    Ann Rheum Dis; 2012 Nov; 71(11):1868-71. PubMed ID: 22833373
    [Abstract] [Full Text] [Related]

  • 11. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.
    Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Rifbjerg-Madsen S, Lorenzen T, Hetland ML.
    Arthritis Rheum; 2011 Feb; 63(2):382-90. PubMed ID: 21279995
    [Abstract] [Full Text] [Related]

  • 12. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG, Mody E, Husni ME, Qureshi AA.
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [Abstract] [Full Text] [Related]

  • 13. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E.
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [Abstract] [Full Text] [Related]

  • 14. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.
    D'Angelo S, Mennillo GA, Cutro MS, Leccese P, Nigro A, Padula A, Olivieri I.
    J Rheumatol; 2009 Feb; 36(2):368-70. PubMed ID: 19208566
    [Abstract] [Full Text] [Related]

  • 15. Emerging drugs for psoriatic arthritis.
    Olivieri I, D'Angelo S, Palazzi C, Lubrano E, Leccese P.
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):399-414. PubMed ID: 20528612
    [Abstract] [Full Text] [Related]

  • 16. Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient care.
    Ruderman EM.
    Am J Manag Care; 2002 Apr; 8(6 Suppl):S171-80. PubMed ID: 11990862
    [Abstract] [Full Text] [Related]

  • 17. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.
    Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS.
    Ann Rheum Dis; 2010 Aug; 69(8):1441-7. PubMed ID: 20525844
    [Abstract] [Full Text] [Related]

  • 18. Psoriatic arthritis: update on pathophysiology, assessment and management.
    Mease PJ.
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i77-84. PubMed ID: 21339225
    [Abstract] [Full Text] [Related]

  • 19. Beyond early diagnosis: occult psoriatic arthritis.
    Palazzi C, Lubrano E, D'Angelo S, Olivieri I.
    J Rheumatol; 2010 Aug 01; 37(8):1556-8. PubMed ID: 20675851
    [No Abstract] [Full Text] [Related]

  • 20. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
    FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, Nab H, Molta C.
    Ann Rheum Dis; 2012 Mar 01; 71(3):358-62. PubMed ID: 21989542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.